BCRX Q3 2023 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$87M+14.4% YoY

Gross Profit

$86M98.7% margin

Operating Income

-$12M-13.7% margin

Net Income

-$36M-41.7% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

+5.2%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$21M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$523M

Total Liabilities

$934M

Stockholders' Equity

-$411M

Cash & Equivalents

$151M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$87M	$76M	+14.4%
Gross Profit	$86M	$72M	+18.5%
Operating Income	-$12M	-$17M	+31.7%
Net Income	-$36M	-$43M	+15.0%

Revenue Segments

Product

$85M98%

Collaborative and Other Research and Development

$1M2%